Skip to main content

Table 2 mNY status at screening and at week 104

From: Two-year imaging outcomes from a phase 3 randomized trial of secukinumab in patients with non-radiographic axial spondyloarthritis

  

Screening

Week 104

mNY-negative

mNY-positive

Single-reader assessmenta

Secukinumab (N = 277)

mNY-negative, n = 209

202/209 (96.7%)

7/209 (3.3%)

mNY-positive, n = 68

11/68 (16.2%)

57/68 (83.8%)

Placebo-secukinumab (N = 139)

mNY-negative, n = 105

102/105 (97.1%)

3/105 (2.9%)

mNY-positive, n = 34

5/34 (14.7%)

29/34 (85.3%)

Two-reader agreementb

Secukinumab (N = 277)

mNY-negative, n = 255

252/255 (98.8%)

3/255 (1.2%)

mNY-positive, n = 22

4/22 (18.2%)

18/22 (81.8%)

Placebo-secukinumab (N = 139)

mNY-negative, n = 121

121/121 (100.0%)

0/121 (0.0%)

mNY-positive, n = 18

4/18 (22.2%)

14/18 (77.8%)

  1. SI joint grade scoring was performed by 2 independent readers (or 3 if adjudicated) who were blinded to the image sequence and treatment assignment. Only patients with both baseline and week 104 assessments are included
  2. mNY modified New York, SI sacroiliac
  3. aA patient was counted as mNY-positive if considered mNY-positive according to at least 1 reader
  4. bA patient is counted as mNY-positive if considered mNY-positive according to at least 2 readers
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us